Beximco Pharmaceuticals Ltd. is a leading Bangladeshi pharmaceutical company established in 1976. It has over 2,500 employees and manufacturing facilities certified by global regulatory bodies. Beximco Pharma produces over 400 products across various therapeutic categories and is the largest exporter of pharmaceuticals in Bangladesh. The company has a growing global presence across five continents and is the only Bangladeshi pharmaceutical company marketing products in the US.

1. Beximco Pharmaceuticals Ltd.
Operational Headquarters
19 Dhanmondi R/A
Road No. 7
Dhaka 1205
Bangladesh.
Telephone: +880-2-8619 151 (5 lines)
Fax: +880-2-8613 888 and +880-2-9663 579
Email: info@bpl.net
Search, View and Navigation
Search.. Search
Font-size:
bigger smaller reset
Home
About Us
Our Products
Health Point
Investor Relations
Latest News
Beximco for Doctors
Contact Us
You are here: Home About Us
About Beximco Pharma

2. Beximco Pharma aspires to become a nationally admired and globally reputed generic
pharmaceutical company, committed to enhancing human health and life.
Beximco Pharmaceuticals Ltd (BPL) is a leading manufacturer of pharmaceutical formulations
and Active Pharmaceutical Ingredients (APIs) in Bangladesh. Beximco Pharma is the flagship
company of Beximco Group, the largest private sector industrial conglomerate in Bangladesh,
and remains the only Bangladeshi company with an AIM listing on the London Stock Exchange.
The company is the largest exporter of pharmaceuticals in the country and its state-of-the-art
manufacturing facilities are certified by global regulatory bodies of Australia, European Union,
Gulf nations, Brazil, among others. The company is consistently building upon its portfolio and
currently producing more than four hundred products in different dosage forms covering broader
therapeutic categories which include antibiotics, antihypertensives, antidiabetics,
antireretrovirals, anti asthma inhalers etc, among many others.
With decades of contract manufacturing experience with global MNCs, skilled manpower and
proven formulation capabilities, the company has been building a visible and growing presence
across the continents offering high quality generics at the most affordable cost.
Ensuring access to quality medicines is the powerful aspiration that motivates more than 2,500
employees of the organization, and each of them is guided by the same moral and social
responsibilities the company values most.
Today Beximco Pharma is building its presence across five continents and is the only
Bangladeshi company to market pharmaceutical products in the USA. The company has a visible
and growing presence in emerging market.
We’ve built Beximco Pharma into one of the most trusted pharmaceutical companies in the
country by delivering solid returns to our shareholders, and helping patients with life-altering
conditions so that they may live their lives to the fullest.
Our Story
Beximco Pharma started its journey back in the 1970‟s. Today the company has grown to
become one of the largest exporters of medicines in the country; employing over 2,500 people
and expanding its presence across many regions of the world.
Let‟s take a look at Beximco Pharma‟s milestones along the way ...
2011: GMP certification from AGES, Austria (Austrian Agency for Health and Food Safety)
2010 : The only pharmaceutical company in Bangladesh to enter the US market through the
acquisition of an Abbreviated New Drug Application (ANDA) for a product; Received GMP
Accreditation from INVIMA, Colombia
2009 : Only Bangladeshi company to receive GMP Certification from ANVISA, Brazil; ION
unit was launched for producing injectables, ophthalmics and nebulizer solutions

3. 2008 : First Bangladeshi company to receive GMP Clearance from Therapeutic Goods
Administration (TGA) Australia, and Gulf Central Committee for Drug Registration, for GCC
states; Technology transfer arrangement to manufacture Roche‟s ARV drug Saquinavir
2007 : Oral Solid Dosage facility was commissioned according to US FDA standards
2006 : Launched CFC free HFA inhalers for the first time in Bangladesh
2005 : Only company in Bangladesh to be listed on the Alternative Investment Market (AIM) of
London Stock Exchange (LSE) through issuance of GDRs
2003 : First and only company to introduce anti-retroviral (ARV) drugs in Bangladesh
2001 : First and only Bangladeshi company to enter Singapore, one of the most regulated
markets in Asia
2000 : Only company to achieve „National Export Trophy (Gold)‟ for the third time
1996 : IV unit (former Beximco Infusions Ltd.) received ISO 9001 Certification from TUV-Cert,
Germany
1993 : Russia became the first export destination for formulation products
1992 : Export operation started with APIs
1985 : Listed on Dhaka Stock Exchange
1983 : Launched its own formulation brands
1980 : Started manufacturing products of Bayer AG, Germany and Upjohn Inc., USA, under
license agreements
1976 : Company incorporated
We have come a long way; but the journey only gets better …
Additional Information
About Us
About Us
o Manufacturing Capabilities
o Regulatory Approvals

4. o Our People
o Research & Development
o Corporate Citizenship
o Global Footprint
o Contract Manufacturing Opportunities
Products & Services
The name Beximco Pharma assures you of many things: outstanding product quality, leading-
edge technology, advanced new products, and a commitment to serve the medical community.
Our products come in a wide range of dosage forms including tablets, capsules, dry syrup,
powder for suspension, cream, ointment, suppositories, metered dose nasal sprays, large volume
intravenous fluids, metered dose inhalers etc. ensuring the global standard of quality.
Healthcare professionals may contact us directly or alternatively the nearest Beximco
Pharma Medical Representatives for further information. Our country regulations do not
allow pharmaceutical companies to offer medical advice or guidance to patients.
Prescription medicines should be taken only as directed by a registered medical practitioner.
Click on the product name for Consumer Medicine Information (CMI).
The CMIs on this website are for Bangladeshi residents only. The CMIs were updated on 1 st
March, 2010 and are static documents.
Our Product Range
Allergic Disorders
Beximco Pharma has a strong focus to offer treatment solutions for both seasonal and perennial
allergic rhinitis. The journey of Beximco Pharma in this arena began with the licensing
arrangement with Bayer AG of Germany for the manufacture and marketing of Incidal® in
Bangladesh . Products in this category also include a proprietary drug, developed by the R & D
team at Beximco Pharma and provides 24-hour relief of allergic rhinitis with congestion
(marketed under the brand name - Pretin® D) Beximco Pharma will continue to build on its
tradition of launching the generic versions of all the research molecules in this category. More...
Analgesics & Antipyretic
Beximco Pharma is the largest provider of analgesic medicines in Bangladesh, led by the strong
performance of Napa® , a preparation of paracetamol. Paracetamol is the safest analgesic in the

5. world for more than 50 years. Napa is the number one brand in terms of unit sales in Bangladesh
and is available in 13 forms and strengths. More...
Anti-infectives
Beximco Pharma is one of the leading companies in the field of antibacterial and antiviral
treatments offering a wide range of products. The anti-infective products of Beximco Pharma are
offered in different dosage forms: Tablet, Capsule, Large volume and Small volume parenterals
for systemic administration and Cream and Ointment for topical administration. Beximco
Pharma is the only company is Bangladesh to manufacture antiviral products to treat most
serious infections of HIV (AIDS). More...
Eye Care
Beximco Pharmaceuticals Ltd has introduced its vision unit in the year 2009. Now Beximco
Pharma got around 20 Ophthalmic products in its product range covering various Therapeutic
groups like Anti-infective, Anti-inflammatory, Artificial Tear, Anti-allergic, Anti-glaucoma and
eye vitamins and minerals etc. Continuous enrichment of ophthalmic product range is going on.
More...
Cardiovascular
Beximco Pharma has always been the leader in Bangladesh cardiovascular market with
innovative product offerings to treat almost all type of cardiovascular diseases like Hypertension,
Coronary Artery Diseases, Hyperlipidemia, Heart Failure, Arrhythmia etc. Beximco Pharma's
amlodipine brand Amdocal® is the number 1 cardiovascular brand since 1996. More...
Central Nervous System
Beximco Pharma has a wide range of CNS medication provide effective treatment of different
diseases involving CNS including anxiety, depression, migraine, epilepsy, insomnia,
schizophrenia, dementia etc. More...
Cough & Cold
Wide product range of Beximco Pharma offers the doctors freedom to choose the right
medication for different types of cough: dry cough, chesty productive cough and other cough
associated with common cold. More...
Endocrine & Diabetes
Beximco Pharma offers wide range of products ensuring effective treatment of type II diabetes.
It has the generic versions of all the leading research molecules including Glipizide, Gliclazide,
Metformin, Glimepiride, Pioglitazone Repaglinide etc. More...

6. Gastrointestinal
Beximco Pharma has a robust product line to treat diseases in the areas of gastroenterology.
Beximco Pharma's Neoceptin®-R, which is a H2 blocker used in the treatment of ulcer, GERD,
and other hyperacidity disorders, is the number one brand in Bangladesh Pharmaceutical Market.
Beximco Pharma will continue to build on its strengths in gastrointestinal category. More...
Intravenous Fluids
Beximco Pharma has a strong product pipeline in the large volume intravenous fluids (IV)
category for the treatment of critically ill patients who are hospitalized or in any emergency
management for the replenishment of body fluids, electrolytes and energy. Beximco Pharma is
also the largest manufacturer of IV fluids in Bangladesh. The products are being manufactured in
its state-of-the-art plant using latest blow form and seal technology which ensures completely
sterile and safe products for the patients. More...
Muscloskeletal
Osteoarthritis, Rheumatoid arthritis, Muscle spasm, pain of musculoskeletal origin are some of
the diseases that limit the activities of daily life of millions of patients. Beximco Pharma with its
wide range of products in the musculoskeletal category offers effective treatment solution forr
those patients. More...
Oncology
Beximco Pharma manufactures a generic version of Tamoxifen (Tamona®) which is being used
successfully world wide for the treatment of breast cancer disease. The company also has a
proven drug for the treatment of nausea and vomiting associated with cancer therapy. More...
Other Products
Beximco Pharma manufactures some other important products also. More...
Vitamins & Minerals Supplement
Beximco Pharma's many brands in the vitamins and nutritional supplement category has gained
trust of the physicians in treating various vitamins and nutritional deficiency symptoms. More...
Respiratory
Beximco Pharma is the leading manufacturer of pressurized Metered Dose Inhalers (MDI) in
Bangladesh and are among the few companies in the world manufacturing CFC
(Chlorofluorocarbon) free MDIs. It has a wide range of inhalers 'Reliever', 'Preventer' and
'Controller' for the treatment of asthma and COPD. The company also undertakes contract
manufacturing for GlaxoSmithKline for its 'reliever' brand. In collaboration with Europe's one of

7. the leading manufacturers of specialty medical devices and respiratory drug development
companies, Beximco Pharma successfully developed and introduced country's fist CFC-free
HFA based MDIs in September 2006. More...
Skin Care
Beximco Pharma's robust product line in the skin care category offers easy and convenient
solution to wide range of skin diseases like fungal and bacterial infections, eczema, atopic
dermatitis, other inflammatory skin diseases requiring corticosteroid therapy, acne, psoriasis, and
various other dry skin problems. More...
Key Company Information
Year of Establishment :: 1976
Country of Incorporation :: Bangladesh
Commercial Production :: 1980
Status :: Public Limited Company
Business Lines :: Manufacturing and marketing of pharmaceutical Finished
Formulation Products, Large Volume Parenterals and Active
Pharmaceutical Ingredients (APIs)
Main Country of operation :: Bangladesh
Corporate Headquarter & :: 17 Dhanmondi R/A, Road No. 2, Dhaka- 1205, Bangladesh
Registered Address Phone : +880-2-8611891 (5 lines)
Fax : +880-2-8613470
Email : info@bpl.net
Operational Headquarters :: 19 Dhanmondi R/A, Road No. 7, Dhaka- 1205, Bangladesh
Phone : +880-2-8619151 (5 lines), +880-2-8619091 (5 lines)
Fax : +880-2-8613888
Email : info@bpl.net
Website : www.beximcopharma.com
Overseas Offices & :: Australia, Bhutan, Cambodia, Chile, Ghana, Hong Kong,
Associates Indonesia, Jordan, Kenya, Kuwait, Malaysia, Myanmar, Nepal,
Pakistan, Philippines,Saudi Arabia, Singapore, Sri Lanka,
Vietnam and Yemen
Authorized Capital (Taka) :: 9,100 million
Paid-up Capital (Taka) :: 2517.6 million
Number of Shareholders :: Around 93,000
:: Dhaka and Chittagong Stock Exchanges of Bangladesh and
Stock Exchange Listings
AIM of London Stock Exchange

8. Number of Employees :: 2,507
TIDM: (Tradable :: BXP
Instrument Display
Mnemonic)
Date shares were admitted :: Dhaka Stock Exchange : 3 July, 1985
to trading Chittagong Stock Exchange : 11June, 1995
AIM ( Alternative 21
:
Investment Market) October,2005
ISIN :: US0885792061
Board Details
Ahmed Sohail Fasiur Rahman
Chairman
Sohail Rahman is the Chairman and founder of Beximco Group. He is a distinguished business
personality of the country and has received many awards and accolades for his outstanding
contribution to country‟s industrial development. Rahman was instrumental in introducing best-
in-class corporate practice in Bangladesh and is widely credited as the architect of Group‟s
successful global strategy.
He graduated with Honours in Physics from the University of Dhaka in 1966, and also studied in
the United Kingdom. Rahman held a number of key positions with many reputed organizations,
serving as the Chairman of IFIC Bank Limited, Director of Industrial Promotion & Development
Company, Director of Arab Bangladesh Bank Limited, Director of Pubali Bank Limited and
Director of the Investment Corporation of Bangladesh.
He is currently a member of the Board of Governors of North South University Foundation, the
first private sector University in Bangladesh. Recently he has been inducted into the Board of
Directors of Dhaka Stock Exchange Ltd.
Ahmed Salman Fazlur Rahman
Vice Chairman
Salman Rahman, younger brother of Sohail Rahman, is co-founder of the Beximco Group. He is
a renowned businessman of the country and is widely acclaimed for his contribution to the
development of private sector. He anchored the key initiatives that have helped build Beximco‟s
corporate identity, and led the Group into becoming a leading industrial conglomerate in the
country.
Besides being the Vice Chairman of Beximco Group of companies, he has held key positions in
many business and industry associations which include President of the Federation of

9. Bangladesh Chambers of Commerce and Industry, President of SAARC Chamber of Commerce
& Industry, President of the Metropolitan Chamber of Commerce & Industry, President of the
Bangladesh Textile Mills Association, among others.
Currently he is the Chairman of Bangladesh Enterprise Institute, a Bangladeshi institute for
private sector advocacy and free market development, President of Bangladesh Association of
Pharmaceutical Industries, President of Bangladesh Association of Publicly Listed Companies ,
Chairman of Abahani Limited, a prominent sporting club in Bangladesh, and Chairman of the
Board of Editors of "The Independent" an English daily newspaper in Bangladesh.
Rahman has many accolades to his name and he holds a degree from Karachi University.
Nazmul Hassan
Iqbal Ahmed
Mohammad Abul Qasem
Osman Kaiser Chowdhury
Dr. Abdul Alim Khan
Abu Bakar Siddiqur Rahman
Ahsanul Karim
Corporate Governance & Committees
The Company has a three-tier management structure, comprising the Board of Directors, the
Executive Committee and the Management Committee. There is also an Audit Committee,

10. constituted in 2006.
The Board is the highest level of authority within the Company comprising mainly non-
executive directors, none of whom receive directors' remuneration from it. The Board meets with
the Executive Committee, comprising six executive directors, twice a year to conduct a full
review of the Company's operations.
Board Details
Executive Committee
Management Committee
Audit Committee
Share Information
Exchanges where quoted and traded
AIM (GDRs* Only)
Dhaka Stock Exchange ( Ordinary Share )
Chittagong Stock Exchange ( Ordinary Share )
*GDRs are not quoted and traded in Dhaka and Chittagong Stock Exchanges
Number of AIM securities in issue: :: 56,457,439 GDRs
Percentage free float :: 100%
Percentage of shares not held in public hands :: 0
Number of shares held in treasury :: 0
Percentage of shares held in treasury :: 0
The identity and percentage holding of significant shareholders (i.e., holder of 3% or more AIM
Securities in issue) are as follows:-

11. No. of GDRs Percentage of
Significant Shareholders
held shares held
HSBC Global Custody Nominees ( UK ) Limited 3.79m 6.17%
Credit Suisse Client Nominees (UK) Limited 8.63m 15.3%
Pershing Nominees Ltd. 6.97m 12.4%
Vidacos Nominees Ltd. 2.70m 4.8%
These however do not include information relating to AIM Securities cleared through Eoroclear
that does not disclose holding because of secrecy under the Belgian Law; and also AIM
Securities held in certificated form (i.e., GDRs physically in the possession of the GDRholders,
not enabling us to furnish the name, address and number of GDRs held by such holders).
Rights of shareholders
AS THE COMPANY IS INCORPORATED IN BANGLADESH (NOT IN UK), IT IS
HEREBY STATED THAT THE RIGHTS OF SHAREHOLDERS OF THE COMPANY
MAY BE DIFFERENT FROM THE RIGHTS OF SHAREHOLDERS IN A UK
INCORPORATED COMPANY
The following sets out a brief summary of the salient provisions of Bangladeshi company law
and regulation relating to rights of shareholders of the Company. It is not, and is not intended to
be, an exhaustive or definitive lists of such rights but is intended merely to provide brief details
and information relating to such rights.
General
The rights of the shareholders (including the holders of AIM Securities) of the Company are
included in the Bangladesh Companies Act 1994, the Bangladesh Securities and Exchange
Ordinance 1969 (together with the Bangladesh Securities and Exchange Commission Act 1993
and the rules made thereunder) and the rules of the Dhaka Stock Exchange (DSE) and the
Chittagong Stock Exchange (CSE); and the Company's Articles of Association.
Shareholders' Meetings
Resolutions to be proposed at shareholders' meetings are classed as either ordinary (requiring a
bare majority in number of shares held by persons who attend and vote at the meeting), or special
or extraordinary (both requiring a 75 per cent. majority in number of shares held by persons who
attend and vote at the meeting).
Bangladesh Companies Act, 1994 requires at least 14 days' notice to be given to shareholders to
call an Annual (or Ordinary) General Meeting (or 21 days if special or extraordinary resolutions

12. are to be proposed at such meeting) and 21 days' notice for an Extraordinary General Meeting.
An Annual General Meeting of the company must be held once per calendar year and no more
than fifteen months after the previous Annual General Meeting. Shareholders should be sent the
audited accounts of the company together with directors' and auditors' reports thereon, proposed
to be laid before such Annual General Meeting together with the notice convening such meeting.
Further, the Annual General Meeting of a listed company for a year is required to be held within
six months of the company's year end.
As in the UK, the holders of not less than one tenth of the issued share capital of a company have
the ability to requisition an extraordinary general meeting.
A shareholder has the right to receive notice of a shareholders' meeting; attend such a meeting;
and raise an issue related to the businesses conducted at any such meeting.
At any general meeting:
1. on a show of hands, every member who is present in person shall have one vote; and
2. on a poll, every member who is present in person or by proxy has one vote for every
share of which he is the holder.
The quorum for a Shareholders' meeting is five persons entitled to vote and present in person. A
proxy representing a Shareholder which is a company may not vote unless his appointment as
proxy has been approved by a resolution of the directors of the appointing company, which
resolution remains in full force and effect at the time of the meeting.
Financial Disclosures
Under the Bangladesh Securities and Exchange Rules, 1987, Bangladeshi listed companies are
obliged to prepare annual audited accounts, audited by a chartered accountant, and to send such
accounts to the Bangladesh SEC, the relevant stock exchanges and all shareholders of such
company at least fourteen days prior to holding of its AGM.
These financial statements, in addition to the requirements of the Securities and Exchange Rules,
1987 and the Bangladesh Companies Act 1994, are required to comply with the International
Accounting Standards as adopted by the Institute of the Chartered Accountants of Bangladesh. In
auditing these financial statements, the auditors are also required to conduct their audit in
conformity with the International Standards of Auditing as adopted by the Institute of the
Chartered Accountants of Bangladesh.
Further, the Bangladesh Securities and Exchange Rules, 1987 require Bangladeshi listed
companies to prepare half-yearly accounts, which do not have to be audited, but do have to be
sent to the Bangladesh SEC, the relevant stock exchanges and all shareholders of such company.
The half-yearly accounts must contain a balance sheet, profit and loss account and cash-flow
statements prepared in the same way as the annual audited accounts are prepared, and must be
sent within one month of the half-year end.

13. Also, a listed company is subject to continuing disclosure requirements pursuant to the Listing
Regulations of the DSE and the CSE. Accordingly, a listed company is required to inform the
Bangladesh SEC, the DSE and the CSE immediately of any ''price sensitive information'' (as
defined above).
In addition, a listed company must notify the Bangladesh SEC, the DSE and the CSE of the
following:
any change in its board of directors; and any change in the holding of each director, officer
and/or other shareholder of the company who is or has been the legal owner of ten per cent. or
above of any class of the company's listed securities at any point of time within seven days of
such change; and
Every transfer of share by the company's sponsors (including every director, promoter and
officer) within seven days of such transfer.
Protection of Minority Interests
Minority shareholders who feel that the Company's affairs are being conducted in a manner
prejudicial to their interests may apply to court for relief in a procedure analogous to that
contained in the UK Companies Act 1985.
Enquiries into the Company's Affairs
The holders of not less than 5 per cent. of the issued share capital of a Bangladeshi listed
company can petition to the Bangladesh SEC to make enquirers into the affairs of the company
in which they hold shares, or its business and transactions, under the Bangladesh Securities and
Exchange Ordinance 1969. If the Bangladesh SEC decides to investigate, it has the power to
require the production of information from the company and its directors, officers and
employees.
Dividends
Under the Bangladesh Securities and Exchange Ordinance,1969 and the rules of the DSE and the
CSE, when a final or interim dividend is approved by the directors of a Bangladeshi listed
company, the DSE, the CSE and the Bangladesh SEC require that decision to be notified to them
within 30 (thirty) minutes. The decision (as notified) will be subject to shareholders' approval in
the Annual General Meeting if the dividend is a final dividend. The dividends must be disbursed
to the shareholders with 60 days of such declaration.
Issue of Shares
The Bangladesh Companies Act, 1994 also gives shareholders pre-emption rights, which may be
disapplied by a resolution of the Directors. However, the Articles of Association of the Company
provide that, subject to a Shareholders' resolution to the contrary, any new shares to be issued
must first be issued to the existing Shareholders pro rata to their holdings.
Issue of Redeemable Shares
A Bangladeshi company may issue and redeem redeemable shares with shareholders' approval in
a meeting.

14. Reduction of Share Capital
A Bangladeshi company may by special resolution reduce its share capital in any manner subject
to Court confirmation in a procedure analogous to that contained in the UK Companies Act,
1985.
Share Buy Back
A Bangladeshi company may buy back its own shares only by way of a court-approved reduction
of capital.
Financial Assistance to Shareholders for Acquisition of Shares
Subject to certain very limited exceptions, the Company, being a public company, must not give
financial assistance to any person for the purposes of the acquisition of any shares in the
Company.
Determination Shareholders' Interests in Shares
As in the UK, the register of members is definitive for determining the members of the
Company.
Removal of Directors
The shareholders of a company may, by extraordinary resolution in a general meeting, remove
any director and appoint a director to fill that vacancy.
Loans to Directors
The Company is not permitted to make any loans to directors or any person connected with a
director, unless the loan is for less than 50 per cent. of the value of the shares in the Company
held by the director; is approved by the Company in a general meeting; is approved by the
directors; and is specifically referred to in the annual report and accounts of the Company.
Sale of Undertaking or Assets
There is no equivalent to the UK Companies Act 1985 provisions requiring the shareholders to
sanction the acquisition or sale of a non-cash asset between a director and the Company.
Under the Bangladesh Companies Act 1994, the directors may not sell the undertaking of the
Company without the consent of the shareholders in a general meeting.
Takeovers and Substantial Acquisitions
The Company is not subject to the City Code on Takeovers and Mergers as, being incorporated
in Bangladesh, the Panel on Takeovers and Mergers does not regard the Company as being
resident in the UK, the Channel Islands or the Isle of Man. As a result, a takeover of the
Company would not be regulated by the UK Panel on Takeovers and Mergers. Under the
Bangladesh Securities and Exchange Ordinance, 1969, companies listed on a Bangladeshi stock
exchange are obliged to disclose to the Bangladesh SEC names and number of all holdings,
amongst others, by any other person or entity of shares representing 10 per cent. or more of the
issued share capital of the company. The Company will be obliged to make such a disclosure in
relation to the Depositary upon Admission but the Company will not be obliged to disclose
details of the holders of GDRs (being the beneficial holders of the New Ordinary Shares) even if

15. any such GDR holder holds GDRs representing more than 10 per cent of the Ordinary Shares
therein issue. The Depositary and the holders of GDRs will not be subject to any disclosure
requirements in Bangladesh.
In addition, the rules of the DSE and CSE require changes in ''substantial shareholdings'' to be
disclosed to the DSE and/or the CSE, as applicable, by the Company. Whilst ''substantial
shareholding'' is not defined and there is no case law on the point, local market practice would
suggest that shareholdings of 10 per cent. and above, and changes to such shareholdings, also
need to be disclosed to the DSE and/or the CSE, by the Company.
Where a shareholder enters into a contract or a memorandum of understanding to acquire 10 per
cent or more of the issued share capital of a Bangladeshi listed company from another
Shareholder, he is obliged, under the Bangladesh Securities and Exchange Commission
(Substantial Acquisition of Shares and Takeovers) Regulations, 2002, to make a public
announcement, through a merchant banker, within three days of such contract or memorandum
of understanding, specifying details of the acquiror including his percentage shareholding in the
relevant company, the salient features of the contract or memorandum of understanding, and, if
the acquiror wishes to make a wider offer to acquire shares, the number of shares that the
acquiror would be prepared to buy from the public together with the terms of such proposed
acquisition. The purchase price of such offer must be the higher of the price agreed under the
contract or memorandum of understanding and the average trading price of the company's shares
during the previous 6 months. A shareholder is not obliged to make an offer to the public in the
public announcement, but is obliged to make a public announcement (including a statement that
he does not intend to make a public offer) upon each acquisition when such shareholder holds in
excess of 10 per cent of the issued share capital of a Bangladeshi listed company. These
regulations will not apply to the Depositary on the issue of the New Ordinary Shares.
If a shareholder does acquire over 90 per cent of the issued share capital of a Bangladeshi listed
company, the shareholder shall make an offer for the shares remaining in public hands.
Bangladeshi law does not have an equivalent provision to the mandatory transfer provisions
contained in section 429 of the UK Companies Act, 1985 which enable an offeror who has
acquired 90 per cent. of the shares in a company to compulsorily acquire the outstanding
minority. However, the Bangladesh Companies Act, 1994 does contain provisions for a court to
sanction a scheme of arrangement (similar to the provisions in section 425 of the UK Companies
Act 1985) and, subject to such court approval, for the mandatory transfer of shares pursuant to a
scheme if the scheme is approved by not less than three quarters of the shareholders, within 120
days of the offer to acquire the entire issued share capital of a company.
Shareholders holding over 10 per cent. of the issued share capital of Bangladeshi listed
companies are not permitted to enter into derivatives contracts referenced to their shares under
which they short sell such shares.
Constitution
The memorandum and articles of association are the constitutional documents of a Bangladeshi
company. A company's memorandum and articles of association (other than the objects clause)

16. may be altered by a special resolution of the shareholders in general meeting. The objects clause
can only be altered subject to confirmation from the Court.
Transfer Restrictions
Because of the following restrictions, purchasers are advised to consult legal counsel prior to
making any offer, resale, pledge or other transfer of the GDRs or the Shares represented thereby.
The AIM Securities (i.e., GDRs) were offered in reliance on Regulation S. The GDRs may not
be offered, sold, pledged or otherwise transferred, directly or indirectly to any person in
Bangladesh or the United States, residents of Bangladesh or the United States, or to, or for the
account or benefit of such persons. The GDRs have not been, and will not be registered under the
US Securities Act 1933, as amended, or with any securities regulatory authority of any state of
the United States or any other jurisdiction, and may only be offered, sold or delivered outside the
United States to persons other than US persons (as defined in Regulation S) in offshore
transactions in reliance on Regulation S, and in accordance with any other applicable law.
Each purchaser of GDRs and each subsequent purchaser of such GDRs will be deemed to have
represented and agreed and acknowledged as follows (terms used herein are defined in
Regulation S):
1. it understands that such GDRs and the underlying Shares have not been, and will not be,
registered under the US Securities Act 1933 or with any securities regulatory authority of
any state of the United States or any other jurisdiction of the United States and are subject
to restrictions on transfer;
2. each purchaser at the time the GDRs are purchased will be, the beneficial owner of such
GDRs and (a) is not a US person and is located outside the United States and (b) is not an
affiliate of the Company or a person acting on behalf of such an affiliate of the Company;
3. it understands that the Master GDR and certificates in definitive form representing the
GDRs (to the extent they are in certificated form), unless otherwise agreed between the
Company and the Depositary, will bear a legend substantially to the following effect:
1. THIS REGULATION S GLOBAL DEPOSITARY RECEIPT AND THE
ORDINARY SHARES OF BEXIMCO PHARMACEUTICALS LTD.
REPRESENTED HEREBY (THE „„SHARES‟‟) HAVE NOT BEEN AND WILL
NOT BE REGISTERED UNDER THE UNITED STATES SECURITIES ACT
1933, AS AMENDED, OR WITH ANY SECURITIES REGULATORY
AUTHORITY OF ANY STATE OR OTHER JURISDICTION OF THE
UNITED STATES.
2. UNLESS THE SHARES HAVE BEEN LISTED ON THE DHAKA STOCK
EXCHANGE AND THE CHITTAGONG STOCK EXCHANGE AND
SUBJECT TO COMPLIANCE WITH BANGLADESHI LAW AND
REGULATION APPLICABLE FROM TIME TO TIME, NO PERSON SHALL
BE ENTITLED TO DEPOSIT FURTHER SHARES, AND NO HOLDER
SHALL BE ENTITLED TO WITHDRAW THE DEPOSITED PROPERTY.

17. 3. THE HOLDER HEREOF, BY PURCHASING THE GDRs REPRESENTED BY
THIS CERTIFICATE, AGREES FOR THE BENEFIT OF BEXIMCO
PHARMACEUTICALS LTD. AND THE DEPOSITARY THAT THE GDRs
MAY NOT, UNLESS EXPRESSLY PERMITTED BY BANGLADESHI LAWS
AND REGULATIONS AT ANY TIME BE OFFERED, SOLD, PLEDGED OR
OTHERWISE TRANSFERRED TO ANY PERSON LOCATED IN
BANGLADESH, TO ANY RESIDENT OF BANGLADESH, OR TO, OR FOR
THE ACCOUNT OR BENEFIT OF, SUCH PERSONS.‟‟
4. The Company, the Depositary, the purchasers and their respective affiliates and others,
will rely upon the truth and accuracy of the foregoing acknowledgements, representations
and agreements.
5. Any offer, sale, pledge, resale or other transfer, or attempted resale or other transfer,
made otherwise than in compliance with the above-stated restrictions shall not be
recognised by the Company or the Depositary in respect of the GDRs or the Shares
represented by the GDRs.
6. Advisers
7.
8. Nominated Adviser
Libertas Capital Corporate Finance Limited
16 Berkeley Street
London W1J 8DZ
UK
9.
10. Broker
Libertas Capital Securities Limited
16 Berkeley Street
London W1J 8DZ
UK
11. Bangladeshi Legal Advisers
to the Company
Huq & Company 47/1,
Purana Paltan
Dhaka 1000, Bangladesh
12. Reporting Accountants
Ernst &Young 1
More Place London
Place London SE1 2AF UK
13. Depositary Bank
Bank of New York
101 Barclay Street
New York
New York 10286
USA
14. Solicitors to the Company
Jones Day 21 Tudor Street London EC4Y 0DJ UK

18. 15. Auditors Messrs.
M. J. Abedin & Co.
National Plaza (6thFloor)
1/G Free School Street
Sonargaon Road
Dhaka 1205,Bangladesh
16. Custodian Bank
HSBC
Anchor Tower, (5thFloor),
1/1-B Sonargaon Road
Dhaka 1205, Bangladesh Nominated Adviser
17. Solicitors to the Placing
Eversheds LLP
Senator House
85 Queen Victoria Street
London EC4V 4JL
UK
18.
19. Public Relations
Financial Dynamics
Holborn Centre
26 Southampton Buildings London WC2 1PB
UK
20.
21. BEXIMCO PHARMACEUTICALS
LTD.
22.
23. 3rd August, 2011
24.
25. Beximco Phrama joins Mobile Alliance for Maternal Action (MAMA)
26.
27. Beximco Pharmaceuticals Limited (“Beximco Pharma” or the “Company”) has joined
Mobile Alliance for Maternal Action (MAMA) in Bangladesh, an innovative coalition to
use mobile phones for delivering life-saving health information to expectant and new
mothers in Bangladesh. The Company has signed an agreement with D.Net, a social
enterprise and the Coalition Coordinator of the MAMA initiative, at a simple ceremony
held at Beximco Pharma‟s Corporate Office on July 19, 2011. Ministry of Health and
Family Welfare (MoHFW) and Access to Information (A2I) Programme at Prime

19. Minister's Office are official partners of the initiative.
28. Read more: Beximco Phrama joins Mobile Alliance for Maternal Action (MAMA)
Beximco Pharma
From Wikipedia, the free encyclopedia
Jump to: navigation, search
Beximco Pharmaceuticals Ltd (DSE : BXPHARMA LSE: BXP), also known as Beximco
Pharma, is a pharmaceutical company in Bangladesh.[1] It is part of the Beximco Group of
Companies.
Beximco Pharmaceuticals Ltd. Bangladesh
Type Limited
Industry Pharmaceutical
Founded 1980
Headquarters Tongi, Dhaka, Bangladesh
Key people Nazmul Hassan (MD)

20. Website beximco-pharma.com
Contents
[hide]
1 Corporate history
2 Factories
3 Philippines
4 References
5 External links
[edit] Corporate history
Beximco Pharma was founded in 1976 and started operations in 1980, manufacturing products
under the licenses of Bayer AG of Germany and Upjohn Inc. of USA. It has now grown to
become a leading pharmaceutical company in Bangladesh, and it supplies more than 10% of
country's total medicinal needs. Today Beximco Pharma manufactures and markets its own
branded generics for several diseases including AIDS, cancer, asthma, hypertension, and
diabetes for both national and international markets.
[edit] Factories
Beximco Pharma manufacturing facilities are spread across a 20-acre (81,000 m2) site located in
Dhaka, Bangladesh. The facilities comprise of a number of purpose-built plants, including a new
Oral Solid Dosage (OSD) plant. The site includes manufacturing facilities as well as a research
laboratory and a number of warehouses. The plant and machinery of the facilities were designed,
produced and installed by partners from Germany, Switzerland, Sweden, Italy and the United
Kingdom, amongst others.
[edit] Philippines
On August, 2007, Beximco exported its medicines to the Philippines, the 5th country of the 10-
member Association of South East Asian Nations (ASEAN) to import Beximco's drugs.
Beximco Managing Director Nazmul Hassan said that exports to the Philippines include metered
dose inhalers, and nasal sprays, and other medications. The Philippine pharmaceutical market
($1.3 billion in 2007), is highly dependent on imported medicines.[2]
[edit] References

21. 1. ^ "BD firm plans to export version of Tamiflu". Daily Times. 2006-04-05.
http://www.dailytimes.com.pk/default.asp?page=2006%5C04%5C05%5Cstory_5-4-
2006_pg5_14. Retrieved 2008-03-08.
2. ^ Reuters, Bangladesh Beximco exports drugs to Philippines
[edit] External links
"Beximco Pharma Official Site". http://www.beximco-pharma.com/.
"Bangladesh Pharmaceutical Society". http://www.pharmadu.net/bps/companyinfo.htm.
Retrieved from "http://en.wikipedia.org/w/index.php?title=Beximco_Pharma&oldid=477012004"
View page ratings
Rate this page
What's this?
Trustworthy
Objective
Complete
Well-written
I am highly knowledgeable about this topic (optional)
I have a relevant college/university degree
It is part of my profession
It is a deep personal passion
The source of my knowledge is not listed here
I would like to help improve Wikipedia, send me an e-mail (optional)

22. We will send you a confirmation e-mail. We will not share your e-mail address with outside parties as
per our feedback privacy statement.
Submit ratings
Saved successfully
Your ratings have not been submitted yet
Your ratings have expired
Please reevaluate this page and submit new ratings.
An error has occured. Please try again later.
Thanks! Your ratings have been saved.
Please take a moment to complete a short survey.
Start survey Maybe later
Thanks! Your ratings have been saved.
Do you want to create an account?
An account will help you track your edits, get involved in discussions, and be a part of the community.
Create an accountorLog in Maybe later
Thanks! Your ratings have been saved.
Did you know that you can edit this page?
Industry Verticals
Textiles |
Pharmaceuticals |
Ceramics |
Real Estate & Trading |
ICT & Media |
Aviation |
Financial Services |
Energy
Welcome to Beximco Pharmaceuticals Ltd.

23. Beximco Pharmaceuticals Ltd (BPL) is a leading manufacturer of pharmaceutical formulations
and Active Pharmaceutical Ingredients (APIs) in Bangladesh. The company is the largest
exporter of pharmaceuticals in the country and its state-of-the-art manufacturing facilities are
certified by global regulatory bodies of Australia, European Union, Gulf nations, Brazil, among
others. The company is consistently building upon its portfolio and currently producing more
than 400 products in different dosage forms covering broader therapeutic categories which
include antibiotics, antihypertensives, antidiabetics, antireretrovirals, anti asthma inhalers etc,
among many others.
With decades of contract manufacturing experience with global MNCs, skilled manpower and
proven formulation capabilities, the company has been building a visible and growing presence
across the continents offering high quality generics at the most affordable cost.
Ensuring access to quality medicines is the powerful aspiration that motivates more than 2,500
employees of the organization, and each of them is guided by the same moral and social
responsibilities the company values most.
Beximco Pharma is a leading edge pharmaceutical company, based in Dhaka, Bangladesh and is
acclaimed for outstanding product quality, world-class manufacturing facilities, product
development capabilities and outstanding service.
We produce and market 'branded generics' for almost all diseases from AIDS to cancer, from
infection to asthma, from hypertension to diabetes, for both national and international markets.
We also manufacture active pharmaceutical ingredients and intravenous fluids and contract
manufacture for major international brands of leading multinational companies. We partner our
activities to the humanities quest for longer, healthier, and happier life.
Specialties
pharmaceutical
less